# Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

> **NCT04305249** · PHASE1 · TERMINATED · sponsor: **Antengene Therapeutics Limited** · enrollment: 36 (actual)

## Conditions studied

- Solid Tumor
- Hematological Malignancy

## Interventions

- **DRUG:** ATG-017
- **DRUG:** ATG-017+Nivolumab

## Key facts

- **NCT ID:** NCT04305249
- **Lead sponsor:** Antengene Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-15
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-05-24
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305249, "Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04305249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*